Please provide your email address to receive an email when new articles are posted on . Global Initiative for Asthma (GINA) guidelines recommend single maintenance and reliever therapy (SMART) for ...

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy, ...

Please provide your email address to receive an email when new articles are posted on . The addition of oral azithromycin to standard treatment improved asthma control and reduced exacerbations ...

Study results suggest immune checkpoint inhibitor therapy may offer immunomodulatory benefits for patients with asthma and ...

Only 15% of patients were adherent to ICS therapy 3 months after their asthma exacerbation, and less that one-fourth of those remained adherent 9 months later. Improved adherence to inhaled ...

PHOENIX, Arizona — In a 15-month phase 4 trial, an inexpensive intervention that can be explained in a single office visit reduced severe exacerbations and improved asthma control in patient ...

(HealthDay News) — For patients with asthma, receipt of immune checkpoint inhibitor (ICI) therapy for melanoma or renal cell carcinoma is not associated with an increased risk for exacerbations, ...

PARIS — Pregnancy is a period of asthma instability; it entails an increased risk for exacerbations. While therapeutic de-escalation, if not the outright cessation of maintenance treatment, is common, ...

Treatment failures occurred in 74% and 45% of patients in the PRED and pooled BENRA groups, respectively, at 90 days. (HealthDay News) — Benralizumab can be used for the treatment of acute ...

Robust real-world data on the effectiveness of biologic therapies in children with severe asthma remain limited, particularly ...